Reduction of Early Reperfusion Injury With the Mitochondria-Targeting Peptide Bendavia
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
We recently showed that Bendavia, a novel mitochondria-targeting peptide, reduced infarction and no-reflow across several experimental models. The purpose of this study was to determine the therapeutic timing and mechanism of action that underlie Bendavia’s cytoprotective property. In rabbits exposed to in vivo ischemia/reperfusion (30/180 min), Bendavia administered 20 minutes prior to reperfusion (0.05 mg/kg/h, intravenously) reduced myocardial infarct size by ∼50% when administered for either 1 or 3 hours of reperfusion. However, when Bendavia perfusion began just 10 minutes after the onset of reperfusion, the protection against infarction and no-reflow was completely lost, indicating that the mechanism of protection is occurring early in reperfusion. Experiments in isolated mouse liver mitochondria found no discernible effect of Bendavia on blocking the permeability transition pore, and studies in isolated heart mitochondria showed no effect of Bendavia on respiratory rates. As Bendavia significantly lowered reactive oxygen species (ROS) levels in isolated heart mitochondria, the ROS-scavenging capacity of Bendavia was compared to well-known ROS scavengers using in vitro (cell-free) systems that enzymatically generate ROS. Across doses ranging from 1 nmol/L to 1 mmol/L, Bendavia showed no discernible ROS-scavenging properties, clearly differentiating itself from prototypical scavengers. In conclusion, Bendavia is a promising candidate to reduce cardiac injury when present at the onset of reperfusion but not after reperfusion has already commenced. Given that both infarction and no-reflow are related to increased cellular ROS, Bendavia’s protective mechanism of action likely involves reduced ROS generation (as opposed to augmented scavenging) by endothelial and myocyte mitochondria.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Anderson, E. J., Lustig, M. E., Boyle, K. E., Woodlief, T. L., Kane, D. A., Lin, C.-T., Price, J. W., Kang, L., Rabinovitch, P. S., Szeto, H. H., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci37048 · Cited by 1,253 · cited 2×
“The protective effects of Bendavia have been attributed to mitochondrial targeted ROS scavenging by the peptide.(17,33) To directly test this hypothesis, ROS production was measured in cell-free ROS-generating systems in the presence or absence of Bendavia.”
BackgroundMethodSelf-citationRadical-free biology of oxidative stress
Jones, D. P. (2008) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00283.2008 · Cited by 1,213
Zhao, K., Zhao, G.-M., Wu, D., Soong, Y., Birk, A. V., Schiller, P. W., & Szeto, H. H. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m402999200 · Cited by 782 · cited 1×
“Our data in isolated heart mitochondria (Figure 6) also show a clear effect in keeping ROS emission low and are consistent with previous studies using mouse liver mitochondria.(57) These studies are promising, yet the findings mostly represent lowered ROS levels.”
ResultMyocardial Protection at a Crossroads: The Need for Translation Into Clinical Therapy
Bolli, R., Becker, L., Gross, G., Mentzer, R., Balshaw, D., & Lathrop, D. A. (2004) · Circulation Research · doi:10.1161/01.res.0000137171.97172.d7 · Cited by 428
The role of the mitochondrial permeability transition pore in heart disease
Halestrap, A. P., & Pasdois, P. (2009) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2008.12.017 · Cited by 362
Tao, Z., Raffel, R. A., Souid, A.-K., & Goodisman, J. (2009) · Biophysical Journal · doi:10.1016/j.bpj.2008.11.071 · Cited by 96 · cited 1×
“These enzymatic systems generate H2O2 and/or superoxide anion as reaction products.(34,35) Because the overwhelming majority of ROS during conditions of oxidative stress are likely nonradical oxidants,(36) the effect of Bendavia on scavenging H2O2 in cell-free systems was examined first.”
Background
Cited by
Mitochondrial dysfunction and oxidative stress in heart disease
Peoples, J. N., Saraf, A., Ghazal, N., Pham, T. T., & Kwong, J. Q. (2019) · Experimental & Molecular Medicine · doi:10.1038/s12276-019-0355-7 · Cited by 950
Mitochondrial function as a therapeutic target in heart failure
Brown, D. A., Perry, J. B., Allen, M. E., Sabbah, H. N., Stauffer, B. L., Shaikh, S. R., Cleland, J. G. F., Colucci, W. S., Butler, J., Voors, A. A., et al. (2017) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2016.203 · Cited by 803
Self-citationKalogeris, T., Bao, Y., & Korthuis, R. J. (2014) · Redox Biology · doi:10.1016/j.redox.2014.05.006 · Cited by 716
Impact of Oxidative Stress on the Heart and Vasculature
Münzel, T., Camici, G. G., Maack, C., Bonetti, N. R., Fuster, V., & Kovacic, J. C. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.05.035 · Cited by 619
Cannistrà, M., Ruggiero, M., Zullo, A., Gallelli, G., Serafini, S., Maria, M., Naso, A., Grande, R., Serra, R., & Nardo, B. (2016) · International Journal of Surgery · doi:10.1016/j.ijsu.2016.05.050 · Cited by 385
Metadata
- Authors
- Brown, D. A., Hale, S. L., Baines, C. P., Rio, C. L. D., Hamlin, R. L., Yueyama, Y., Kijtawornrat, A., Yeh, S. T., Frasier, C. R., Stewart, L. M., Moukdar, F., Shaikh, S. R., Fisher-Wellman, K. H., Neufer, P. D., & Kloner, R. A.
- Venue
- Journal of Cardiovascular Pharmacology and Therapeutics
- Publisher
- SAGE Publications
- Published
- 2013-11-28
- Volume
- 19
- Issue
- 1
- Pages
- 121-132
- ISSN
- 1074-2484 (ISSN-L)
- 1940-4034
- OpenAlex
- W2143049896
- Cited by
- 110
- References
- 6
- FWCI
- 5.78
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.